Pfizer Doses First Participant in Phase 3 Study Evaluating anti-TFPI Investigational Therapy, Marstacimab, for People With Severe Hemophilia A and B With or Without Inhibitors
– If approved, marstacimab has potential to be a best-in-class treatment option among novel non-factor agents – NEW YORK-(BUSINESS WIRE)-
Read more